a public good project by the
Synthesis
Company
of California

© 2026

Ellen C. Zwarthoff | doi.page

0 works0 citations0 h-index

Ellen C. Zwarthoff

Erasmus MC(NL)Erasmus MC Cancer Institute(NL)

Publications by Year

Research Areas

Bladder and Urothelial Cancer Treatments, Urinary and Genital Oncology Studies, Epigenetics and DNA Methylation, Fibroblast Growth Factor Research, Cancer Genomics and Diagnostics

Most-Cited Works

→ Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy(2017)779 cited
→ Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma(2016)645 cited
→ Efficient rescue of integrated shuttle vectors from transgenic mice: a model for studying mutations in vivo.(1989)492 cited
→ An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer(2021)361 cited
→ Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome(2003)320 cited
→ FGFR3, HRAS, KRAS, NRAS and PIK3CA Mutations in Bladder Cancer and Their Potential as Biomarkers for Surveillance and Therapy(2010)

310 cited

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.(2001)

→ Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines(2009)303 cited

→ Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome(2013)285 cited

→ FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma(2004)221 cited